HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- n- butyl- 9- methyl- 8- (1,2,3)triazol- 2- yl- 9H- purin- 6- ylamine

structure in first source

Also Known As:

ST 1535; ST-1535; ST1535

Networked: 7 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - 2-n-butyl-9-methyl-8-(1,2,3)triazol-2-yl-9H-purin-6-ylamine: 7
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Adenine: 2120
        2-n-butyl-9-methyl-8-(1,2,3)triazol-2-yl-9H-purin-6-ylamine: 7

Experts

1.	Borsini, Franco: 5 articles (08/2015 - 10/2006)
2.	Minetti, Patrizia: 3 articles (08/2015 - 10/2006)
3.	Stasi, Maria Antonietta: 3 articles (08/2015 - 10/2006)
4.	Carminati, Paolo: 3 articles (07/2007 - 09/2006)
5.	Riccioni, Teresa: 2 articles (08/2015 - 07/2013)
6.	Frau, Lucia: 2 articles (03/2011 - 07/2007)
7.	Morelli, Micaela: 2 articles (03/2011 - 07/2007)
8.	Schintu, Nicoletta: 2 articles (03/2011 - 07/2007)
9.	Jenner, Peter: 2 articles (02/2007 - 09/2006)
10.	Rose, Sarah: 2 articles (02/2007 - 09/2006)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 10/01/2006 - "ST 1535 represents a potential new compound, with long-lasting activity, for the treatment of Parkinson's disease." 02/16/2007 - "ST1535 may be useful in the treatment of Parkinson's disease and effective in reducing the use of l-dopa." 07/11/2013 - "Synthesis and biological evaluation of metabolites of 2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), a potent antagonist of the A2A adenosine receptor for the treatment of Parkinson's disease." 09/28/2006 - "The data suggests that ST1535 will be an effective anti-parkinsonian agent in combination with L-DOPA and allow a reduction in l-DOPA usage in the treatment of Parkinson's disease." 07/02/2007 - "Finally, acute administration of ST1535 (20 mg/kg i.p.) proved capable of reducing jaw tremors in tacrine model of Parkinson's disease tremor. "
2.	Catalepsy 10/01/2006 - "At oral doses ranging between 5 and 20 mg/kg, ST 1535 induces hypermotility and antagonizes haloperidol-induced catalepsy in mice up to 7 h. " 10/01/2006 - "Oral ST 1535, at 1.25 and 2.5 mg/kg, potentiates L-dopa effects in reducing haloperidol-induced catalepsy. " 10/01/2006 - "ST 1535, at oral doses of 5 and 10 mg/kg, antagonizes catalepsy induced by intracerebroventricular administration of the A2A adenosine agonist CGS 21680 (10 microg/5 microl) in mice. " 08/15/2015 - "ST1535, ST3932 and ST4206 antagonized (orally) haloperidol-induced catalepsy in mice, potentiated (intraperitoneally) the number of contralateral rotations induced by l-3,4-dihydroxyphenylalanine (l-DOPA) (3mg/kg) plus benserazide (6mg/kg) in 6-Hydroxydopamine hydrobromide (6-OHDA)-lesioned rats, and increased mouse motor activity by oral route. "
3.	Dyskinesias (Dyskinesia) 07/02/2007 - "Subchronic (18 days, twice a day) ST1535 (20 mg/kg i.p.)+L-DOPA (3 mg/kg i.p.) did not induce sensitization to turning behaviour or abnormal involuntary movements during the course of treatment, indicating a low dyskinetic potential of the drug. "
4.	Tremor (Tremors) 07/02/2007 - "Finally, acute administration of ST1535 (20 mg/kg i.p.) proved capable of reducing jaw tremors in tacrine model of Parkinson's disease tremor. "

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Haloperidol (Haldol)
3.	Adenosine A2A Receptor (Adenosine A2A Receptors)
4.	Purinergic P1 Receptors (Adenosine Receptor)
5.	Oxidopamine (6 Hydroxydopamine)
6.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
7.	Tacrine (Cognex)
8.	Benserazide
9.	Adenosine (Adenocard)
10.	2- (4- (2- carboxyethyl)phenethylamino)- 5'- N- ethylcarboxamidoadenosine